Patnaik, A.; Hamilton, E.; Xing, Y.; Rasco, D.W.; Smith, L.; Lee, Y.-L.; Fang, S.; Wei, J.; Hui, A.-M.
A Phase I Dose-Escalation and Dose-Expansion Study of FCN-437c, a Novel CDK4/6 Inhibitor, in Patients with Advanced Solid Tumors. Cancers 2022, 14, 4996.
https://doi.org/10.3390/cancers14204996
AMA Style
Patnaik A, Hamilton E, Xing Y, Rasco DW, Smith L, Lee Y-L, Fang S, Wei J, Hui A-M.
A Phase I Dose-Escalation and Dose-Expansion Study of FCN-437c, a Novel CDK4/6 Inhibitor, in Patients with Advanced Solid Tumors. Cancers. 2022; 14(20):4996.
https://doi.org/10.3390/cancers14204996
Chicago/Turabian Style
Patnaik, Amita, Erika Hamilton, Yan Xing, Drew W. Rasco, Lon Smith, Ya-Li Lee, Steven Fang, Jiao Wei, and Ai-Min Hui.
2022. "A Phase I Dose-Escalation and Dose-Expansion Study of FCN-437c, a Novel CDK4/6 Inhibitor, in Patients with Advanced Solid Tumors" Cancers 14, no. 20: 4996.
https://doi.org/10.3390/cancers14204996
APA Style
Patnaik, A., Hamilton, E., Xing, Y., Rasco, D. W., Smith, L., Lee, Y. -L., Fang, S., Wei, J., & Hui, A. -M.
(2022). A Phase I Dose-Escalation and Dose-Expansion Study of FCN-437c, a Novel CDK4/6 Inhibitor, in Patients with Advanced Solid Tumors. Cancers, 14(20), 4996.
https://doi.org/10.3390/cancers14204996